Shares of MyoKardia are soaring about 60% in Monday’s pre-market trading after the biopharma company agreed to be acquired by Bristol Myers Squibb …
With the outbreak of the coronavirus, volatility has become a seemingly ever-present facet of the stock market. Since the end of February, the …
Written by Danny Cohen and Scott Matusow The biotech “run-up” trade has always attracted a wide-array of traders looking to take advantage of …
Shares of Myokardia Inc (NASDAQ:MYOK) are down nearly 3% Tuesday as investors digest the biotech firm’s third-quarter financial results. The company reported Q3 EPS …
It is a nice time to be a Myokardia Inc (NASDAQ:MYOK) investor, particularly on back of the biotech firm’s successful Phase 2a PIONEER …
Upon releasing positive data for lead drug candidate Mavacamten on Monday, investors flocked to Myokardia Inc (NASDAQ:MYOK), sending the stock soaring by 83%. …
Healthcare analysts expressed their opinions on Myokardia Inc (NASDAQ:MYOK) and Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) after the former released promising clinical data in symptomatic, obstructive hypertrophic …
Written by Dan Cohen and Scott Matusow Currently, we are in the midst of a dramatic shift in the field of biotechnology and …
